TrivarX (ASX:TRI) has reported positive results from its clinical trial with the Greater Los Angeles Research and Education Foundation and the Veterans Affairs Greater Los Angeles Healthcare System, evaluating its single-lead ECG algorithm for screening current major depressive episodes in veterans with suspected sleep apnea.
The trial, involving 57 of 60 enrolled participants, showed that the single-lead algorithm achieved a sensitivity of 97% and specificity of 64% for detecting cMDE, closely aligning with the performance of TrivarX's lead asset, MEB-001, which demonstrated 88% sensitivity and 68% specificity.
The study also highlighted the high prevalence of sleep disturbance, depression, and post-traumatic stress disorder in veterans, with 58% of participants diagnosed with cMDE and 72% of those also experiencing PTSD.
By using only heart rate and heart rate variability metrics, TrivarX's single-lead platform offers a scalable, objective, and clinically meaningful approach to mental health screening that can be integrated into existing clinical workflows, including VA sleep clinics, without additional operational burden.
Principal Investigator Dr. Jennifer Martin noted the approach enables detection of mental health symptoms in patients who may otherwise go unassessed, while Non-Executive Chairman David Trimboli emphasised that the results validate the real-world utility of TrivarX's technology and strengthen its commercial and regulatory positioning.